Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Reapplix A/S has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution is currently handled by 1 distinct examiner and 1 distinct art unit, indicating a concentrated effort on a specific biotechnology. This structure allows for a focused legal strategy, as the company only needs to address the concerns of 1 individual at the patent office. However, it also means that the company's current patent prospects are dependent on that examiner's review.
The busiest examiner for the portfolio is HELM, CARALYNNE E, who is responsible for the 1 busiest examiner pending office action. This examiner is the 1 currently reviewing the company's pending work, so their perspective on the biological and pharmaceutical claims is critical. Because there is 1 distinct examiner and 1 distinct art unit, the company can tailor its responses to a specific set of examination standards. Resolving the 1 pending office action will require a precise response to the specific issues identified by this examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250049 | BLOOD PRODUCT FOR PREVENTING SURGICAL ADHESION | HELM, CARALYNNE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250049 | BLOOD PRODUCT FOR PREVENTING SURGICAL ADHESION | HELM, CARALYNNE E | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18250049 | BLOOD PRODUCT FOR PREVENTING SURGICAL ADHESION | HELM, CARALYNNE E | 1615 | §112 | Non-Final OA | — | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial